author-photo

Jeffrey Ciavarri

Takeda Pharmaceutical Company

6

Papers

11

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome.

2021 Proceedings of the National Academy of Sciences of the United States of America
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 3719: TAK-243, a small molecule inhibitor of the ubiquitin activating enzyme (UAE), disrupts DNA damage repair and sensitizes tumor cells and xenografts to ionizing radiation

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
577 Characterization of the cellular mechanism of action of the first in class investigational inhibitor of the Ubiquitin Activating Enzyme, MLN7243

2014 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (6)
255 Pre-clinical in vivo characterization of MLN7243, an investigational ubiquitin activating enzyme inhibitor, in solid tumor models

2014 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (3)
561 Nonclinical characterization of the first in class investigational ubiquitin activating enzyme inhibitor MLN7243 in cellular and in vivo models of cancer in support of a phase I study

2014 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models

2013 Blood
Show All
- Source
- Cite
- Save
Citations (1)